ADARx (ADRX) CSO Alan MacLeod Receives Award of 170,692 Shares

What Happened

• Alan MacLeod, Chief Scientific Officer of ADARx Pharmaceuticals (ADRX), received a grant/award of 170,692 derivative shares on 2026-09-24. The reported acquisition price is $0.00 on the Form 4 (code A — grant/award/other acquisition).

Key Details

• Transaction date and price: 2026-09-24; reported acquisition price $0.00 (derivative award).
• Vesting: 1/4 of the award vests and becomes exercisable on September 24, 2027; the remaining shares vest in equal quarterly installments over the following three-year period, subject to continued service (see footnote).
• Shares owned following the transaction: Not specified in the Form 4 filing.
• Filing timeliness: Form 4 was filed on 2026-09-28 (within the standard two business-day reporting window for a 9/24 transaction), so the report appears timely.

Context

• This was a time-based equity award (derivative grant) rather than an open-market purchase or sale. Such awards are commonly used for employee compensation and vest over time subject to continued service; they do not represent an immediate cash purchase or sale and do not by themselves indicate a trading intent.